Skip to main content
. 2022 Sep 7;8(2):e002359. doi: 10.1136/rmdopen-2022-002359

Figure 2.

Figure 2

Efficacy of biological disease modifying antirheumatic drugs targeting the IL-6 receptor or ligand and their relative efficacy and/or regulatory approvals across immune-mediated inflammatory diseases (based on available data at end of December 2020). aNCT02991469 (recruiting); bNCT02776735 (recruiting); cNCT03600805 (study terminated, results are awaited); d trial terminated early due to sponsor decision. For colorblind readers, figure 2 is provided in the online supplemental appendix (section 7: S7.1). EU, European Union; JPN, Japan; RU: Russian Federation; US: United Stated of America.